» Articles » PMID: 12398558

Drug-drug Interactions in the Elderly

Overview
Specialty Pharmacology
Date 2002 Oct 26
PMID 12398558
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To detect the frequency of potential drug-drug interactions (DDIs) in an outpatient group of elderly people in 6 European countries, as well as to describe differences among countries.

Data Sources And Methods: Drug use data were collected from 1601 elderly persons living in 6 European countries. The study population participated in a controlled intervention study over 18 months investigating the impact of pharmaceutical care. Potential DDIs were studied using a computerized detection program.

Results: The elderly population used on average 7.0 drugs per person; 46% had at least 1 drug combination possibly leading to a DDI. On average, there were 0.83 potential DDIs per person. Almost 10% of the potential DDIs were classified to be avoided according to the Swedish interaction classification system, but nearly one-third of them were to be avoided only for predisposed patients. The risk of subtherapeutic effect as a result of a potential DDI was as common as the risk of adverse reactions. Furthermore, we found differences in the frequency and type of potential DDIs among the countries.

Conclusions: Potential DDIs are common in elderly people using many drugs and are part of a normal drug regimen. Some combinations are likely to have negative effects; more attention must be focused on detecting and monitoring patients using such combinations. As differences in potential DDIs among countries were found, the reasons for this variability need to be explored in further studies.

Citing Articles

Design-assisted HPLC-UV method for therapeutic drug monitoring of pholcodine, ephedrine, and guaifenesin in biological fluids.

Roshdy A, Abdel Salam R, Hadad G, Belal F, Elmansi H Sci Rep. 2024; 14(1):27933.

PMID: 39537794 PMC: 11560963. DOI: 10.1038/s41598-024-78793-6.


Assessment of co-ingestion effects on poisoning patterns, drug-drug interactions, and adverse outcomes in acute toxic exposure.

Sharif A, Alshammari R, Alghamdi F, Almutairi S, Alghamdi A, Al-Nazhan A Toxicol Rep. 2024; 13:101705.

PMID: 39224455 PMC: 11367109. DOI: 10.1016/j.toxrep.2024.101705.


Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.

Sanchez-Valle J, Correia R, Camacho-Artacho M, Lepore R, Mattos M, Rocha L BMC Med. 2024; 22(1):166.

PMID: 38637816 PMC: 11027217. DOI: 10.1186/s12916-024-03384-1.


Deprescribing in Older Poly-Treated Patients Affected with Dementia.

Gareri P, Gallelli L, Gareri I, Rania V, Palleria C, De Sarro G Geriatrics (Basel). 2024; 9(2).

PMID: 38525745 PMC: 10961769. DOI: 10.3390/geriatrics9020028.


Potential drug-drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey.

Albayrak A, Duzenli T, Kayikcioglu E J Cancer Res Clin Oncol. 2023; 149(12):9621-9627.

PMID: 37222813 DOI: 10.1007/s00432-023-04890-0.